Peripherin and periaxin, biomarkers of peripheral axonal damage and demyelination, respectively, have recently been validated in Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This evidence concerns the gene PRX and Guillain-Barre syndrome.